TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05938725

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“Study discontinued due to sponsor decision.”

The sponsor’s own words in the registry.

Life of this trial

202220232024202520262027Registered2022-10-11Started2023-04-28Stopped2026-05-29

Vital statistics

Status
Terminated
Phase
Phase 1, Phase 2
Sponsor
Kyverna Therapeutics
Sponsor type
Industry
Conditions
Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III; Lupus Nephritis - WHO Class IV
Interventions
KYV-101 anti-CD19 CAR-T cell therapy; Standard lymphodepletion regimen
Participants
6
Sites
6
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.